Edwards Lifesciences Corporation
) is scheduled to report its fourth-quarter and full year 2012
results after the market closes on Monday, Feb 4, 2013. Last
quarter, this medical device major posted a positive earnings
surprise of 3.57%. Let's see how things are shaping up prior to
Edwards' Growth Profile in the Past Quarter
Edwards Lifesciences faced a challenging third quarter with
dismal performance in the overseas market, especially Europe
where it battles a contagion of economic problems. Adding to the
concern is the foreign exchange headwind. Moreover, the lower
transcatheter heart valve (THV) sale in the domestic market
dragged the top-line. Thus, the third-quarter results led to a
lower, dull outlook for 2012.
While recent product approvals and foothold expansion in
lucrative markets might help Edwards overcome its challenges, it
also gears for an improved execution in 2013.
Our proven model does not conclusively suggest that Edwards is
likely to beat earnings estimate this quarter. This is because a
stock needs to have a positive Earnings ESP (Read:
Zacks Earnings ESP: A Better Method
) as well as a Zacks Rank of #1, 2 or 3 for this to happen. This,
however, is not the case for Edwards as seen below:
Negative Zacks Earnings ESP:
The Most Accurate estimate stands at $0.76 while the Zacks
Consensus Estimate is $0.77. This translates to an Earnings ESP
Zacks Rank #2 (Buy):
Although Edwards' Zacks Rank #2 when combined with negative ESP
makes the surprise prediction difficult, the odds of a positive
surprise turnout are lower.
Other Stocks to Consider
Here are some other companies that warrant a look as they have
the right ingredients to report possible earnings beat this
), Earnings ESP of +2.56% and Zacks Rank #1 (Strong Buy)
Becton Dickinson and Company
), Earnings ESP of +3.25% and Zacks Rank #2 (Buy)
Henry Schein Inc.
), Earnings ESP of +0.83% and Zacks Rank #3 (Hold).
BECTON DICKINSO (BDX): Free Stock Analysis
CYBERONICS INC (CYBX): Free Stock Analysis
EDWARDS LIFESCI (EW): Free Stock Analysis
HENRY SCHEIN IN (HSIC): Free Stock Analysis
To read this article on Zacks.com click here.